The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Increases speed to market for drug developers working on nucleic acid therapeutics
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
Subscribe To Our Newsletter & Stay Updated
